503A vs 503B Compounding Pharmacies 2026 - GLP-1 Sourcing Guide

If you are taking compounded semaglutide or tirzepatide, a pharmacy somewhere made it. Which pharmacy, and under which regulatory category, determines the level of oversight applied to its manufacturing — and most patients have never been told either.

This matters more in 2026 than it did two years ago. With semaglutide and tirzepatide both off the FDA drug shortage list, the broad legal basis for routine compounding of copies ended, and the FDA has published concerns about unapproved GLP-1 drugs used for weight loss.

The One-Sentence Version

503A pharmacies compound for individual patient prescriptions and are regulated primarily by state boards of pharmacy. 503B outsourcing facilities register with the FDA, must comply with current good manufacturing practice requirements, and are subject to FDA inspection.

Neither produces an FDA-approved drug. But the manufacturing oversight differs meaningfully, and you are entitled to know which applies to you.

The Two Categories Compared

	503A Compounding Pharmacy	503B Outsourcing Facility
Primary regulator	State boards of pharmacy	FDA registration, plus state oversight
Manufacturing standard	USP compounding standards including USP <797> for sterile preparations	Current good manufacturing practice (cGMP)
FDA inspection	FDA has enforcement authority over compliance	Subject to FDA inspection as registered facilities
Prescription requirement	Compounds against individual patient prescriptions	May compound larger batches without patient-specific prescriptions
Typical scale	Community sterile compounding	Larger batch production
FDA-approved product?	No	No

Neither Is ’Fake’ and Neither Is FDA-Approved

Both categories are legitimate parts of US pharmacy practice with a long history predating GLP-1s entirely. A 503A pharmacy is not a back-room operation.

But equally, neither produces an FDA-approved medication. A compounded preparation has not been reviewed by the FDA for safety, efficacy or manufacturing quality, regardless of which category prepared it.

Why It Matters More Now

During the shortage, compounding copies of semaglutide and tirzepatide was straightforwardly permitted because both drugs appeared on the FDA drug shortage list. Both have since come off it, which removed that specific justification.

Compounding continues in narrower circumstances, and providers describe the basis differently — which is why so many platforms moved to ’personalized formulation’ language, combining GLP-1s with B12, B6, glycine or other additives. Whether any specific arrangement is appropriate is a question about that pharmacy and that prescription, not something a patient can determine from a website.

In that environment, the identity and category of the dispensing pharmacy is the most useful single piece of information a patient can obtain — and a provider’s willingness to supply it is itself informative.

What Providers Actually Disclose

Disclosure across this market ranges from exemplary to non-existent.

Disclosure Level	What It Looks Like	Examples
Names pharmacy and licence	Specific facility plus a verifiable state board licence number	Trimi — VialsRx, TX licence #35264, and GreenwichRx
States the tier upfront	Discloses 503A or 503B without being asked	Coreage RX (503B), Fifty 410 (503A)
Acknowledges both tiers	States it works with 503A and 503B facilities	Shapely
Generic description only	’A licensed US compounding pharmacy’ with no further detail	Several providers, including some we rate positively
No disclosure	Nothing published; requires a direct request	Common across the market

A Provider Worth Copying

Trimi publishes its pharmacy partners with a verifiable Texas State Board of Pharmacy licence number, identifies its medical director, and maintains a guide teaching patients how to confirm a sterile-compounding licence independently.

A company that teaches you how to check its work is behaving differently from one that hopes you will not. That is the standard worth holding others to.

How to Verify Your Pharmacy

Ask for the pharmacy’s name

Not ’a licensed US compounding pharmacy’ — an actual name. You are entitled to know who is making a medication you inject weekly.

Ask whether it is 503A or 503B

Both are legitimate. The oversight differs. If two providers are close on price and one uses a 503B outsourcing facility, that is a reasonable tiebreaker.

Look it up with the state board of pharmacy

Every state board maintains a licensee lookup. If you have a licence number, verification takes a few minutes. If the pharmacy is out of state, check the board where it is located.

Check the FDA’s registered outsourcing facility list for 503B claims

The FDA publishes a list of registered outsourcing facilities. A provider claiming 503B sourcing should name a facility that appears on it.

Ask about third-party testing

Reputable operations conduct potency and sterility testing and will say so. Ask whether results are available for your lot.

Ask what is in the formulation

If your preparation includes B6, B12 or glycine, ask what doses. Sustained high vitamin B6 intake carries a documented dose-dependent risk of peripheral neuropathy, so this is a real clinical question rather than a curiosity.

Answers That Should Concern You

Hard Stops

Regardless of price, these should end your consideration of a provider:

Refusal to name the pharmacy. There is no legitimate reason to withhold this from the patient taking the medication.
Products labelled ’for research purposes only’ or ’not for human consumption’. The FDA has warned specifically about these.
GLP-1 compounds that are not approved molecules, such as retatrutide. The FDA has cited telehealth companies for marketing unapproved drugs including retatrutide directly to consumers.
No genuine medical consultation. If nobody reviews your history, nobody is checking your contraindications.
Claims that a compounded product is FDA-approved. It is not, by definition. A provider saying otherwise is either confused or misleading you.

The Bottom Line

503A pharmacies compound against individual prescriptions under state board regulation and USP standards. 503B outsourcing facilities register with the FDA, follow current good manufacturing practice, and face FDA inspection. Both are legitimate; neither produces an FDA-approved drug.

Since semaglutide and tirzepatide left the FDA shortage list, sourcing has become the most consequential question a compounded patient can ask. The regulatory ground shifted, and provider practices vary widely in response.

Ask for the pharmacy name and tier, then verify it yourself through the relevant state board of pharmacy. It takes minutes, and a provider’s willingness to answer tells you as much as the answer does.

For providers ranked with sourcing transparency weighted heavily, see our compounded provider guide. For what changed regulatorily, see compounded GLP-1s after the shortage ended.

Frequently Asked Questions

What is the difference between 503A and 503B?

503A pharmacies compound medications against individual patient prescriptions and are regulated primarily by state boards of pharmacy under USP standards, including USP <797> for sterile preparations. 503B outsourcing facilities register with the FDA, must comply with current good manufacturing practice requirements, may compound larger batches without patient-specific prescriptions, and are subject to FDA inspection.

Is 503B safer than 503A?

503B facilities operate under a higher and more standardised manufacturing oversight regime. That does not make every 503A pharmacy inferior in practice — many are excellent — but if two providers are otherwise comparable, 503B sourcing is a reasonable tiebreaker.

Does either produce FDA-approved medication?

No. Compounded preparations from both categories are not FDA-approved and have not been reviewed by the FDA for safety, efficacy or manufacturing quality. The active ingredient may be FDA-approved in a commercial formulation; the compounded preparation is not.

How do I find out which pharmacy makes my medication?

Ask your provider directly for the pharmacy’s name and category. Some providers publish it — Trimi names VialsRx with a Texas State Board of Pharmacy licence number and GreenwichRx. Many do not publish it but will answer if asked.

How do I verify a compounding pharmacy licence?

Every state board of pharmacy maintains a licensee lookup. With a licence number, verification takes a few minutes. For a facility claiming 503B status, the FDA publishes a list of registered outsourcing facilities you can check against.

Why do so many providers add B12 or B6 to the formulation?

Combining a GLP-1 with additional ingredients creates a preparation that is not a straight copy of a commercially available drug, which occupies different legal territory. It is also marketed around tolerability and energy. The weight-loss benefit is generally not established by strong evidence, and sustained high vitamin B6 intake carries a documented neuropathy risk — ask what dose you are receiving.

What if my provider will not tell me the pharmacy?

Treat that as a reason to look elsewhere. You are injecting this medication weekly; knowing who manufactured it is a reasonable baseline expectation, and a refusal is informative about how the provider operates.

Should I switch to brand-name instead?

It is worth pricing. Brand-name oral GLP-1s now start around $149 per month self-pay through manufacturer channels, which is competitive with mid-tier compounded providers while carrying full FDA approval. If you are paying $250 or more for compounded medication, compare before renewing.

⚕️ Medical Disclaimer:

This article is for informational purposes only and is not medical advice, diagnosis, or treatment. GLP-1 receptor agonists are prescription medications with serious risks and contraindications, including a boxed warning for thyroid C-cell tumors. Only a licensed clinician who knows your medical history can determine whether any weight-management medication is appropriate for you. See our full medical disclaimer.

Disclosure:

This article is based on publicly available FDA communications and public information about US pharmacy compounding categories, plus provider-published materials, current as of August 2026. Presidential GLP-1 may receive compensation from some providers featured on this site, which helps us provide free, independent reviews — including providers named as positive disclosure examples here, which is why we cite the specific verifiable practices rather than asking you to take our word for it. This is a plain-language summary and is not legal advice; the regulation of pharmacy compounding is complex and continues to develop through regulatory action and litigation. Pharmacy licence details cited are as published by providers and can be independently verified through the relevant state board of pharmacy. Nothing here is medical advice.

503A vs 503B: Who Actually Makes Your Compounded GLP-1?